Related Experiment Video

Updated: Jan 24, 2026

Crystal Structure of the N-terminal Domain of Ryanodine Receptor from Plutella xylostella
11:31

Crystal Structure of the N-terminal Domain of Ryanodine Receptor from Plutella xylostella

Published on: November 30, 2018

7.9K

Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies

Francesco Bertoni1, Anastasios Stathis2

  • 1Università della Svizzera italiana, Istituto Oncologico di Ricerca.

Current Opinion in Hematology
|May 23, 2019
PubMed
Abstract

Insights

Bromodomain and Extra-Terminal (BET) inhibitors are promising epigenetic therapies for lymphoma. Preclinical data show antitumor activity, and ongoing research aims to optimize their use and identify responsive patients.

Area of Science:

  • Epigenetics
  • Cancer Therapeutics
  • Lymphoma Research

Background:

  • Bromodomain and Extra-Terminal (BET) proteins play a crucial role in gene transcription.
  • Inhibition of BET proteins significantly impacts lymphoma cells.
  • BET inhibitors demonstrate preclinical antitumor activity in various lymphoma models.

Purpose of the Study:

  • To review the current landscape of BET inhibitors in lymphoma treatment.
  • To discuss the mechanism of action and clinical evaluation of BET inhibitors.
  • To explore future directions for optimizing BET inhibitor therapy in lymphomas.

Main Methods:

  • Review of recent preclinical and clinical data on BET inhibitors in lymphomas.
  • Analysis of the mechanism of action of BET protein inhibition.
  • Evaluation of combination strategies and patient stratification for BET inhibitor therapy.

Main Results:

  • BET inhibitors exhibit significant preclinical antitumor activity as single agents and in combination therapies.
  • Early clinical data suggest potential therapeutic activity in lymphoma patients.
  • Ongoing research focuses on improving efficacy and identifying predictive biomarkers.

Conclusions:

  • BET proteins are validated therapeutic targets in lymphoma.
  • Further development of novel BET inhibitors and combination regimens is warranted.
  • Personalized approaches to identify patients most likely to benefit from BET inhibition are crucial for future clinical success.

More Related Videos

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K
Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy05:24

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy

Published on: January 10, 2025

785

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Conservation of Protein Domains Over Different Proteins02:26

Conservation of Protein Domains Over Different Proteins

Protein domains are small structurally independent units that are part of a single amino acid chain.  Although these domains are often structurally independent, they may rely on synergistic effects to perform their functions as part of a larger protein. Protein domains may be conserved within the same organism, as well as across different organisms.
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
14.1K
Termination of Translation01:44

Termination of Translation

The large ribosomal subunit has several important structures essential to translation. These include the peptidyl transferase center (PTC) - which is the site where the peptide bond is formed - and a large, internal, water-filled tube through which the nascent polypeptide moves. This latter structure is called the Peptide Exit Tunnel, and it begins at the PTC and spans the body of the large ribosomal subunit. During translation, as the nascent polypeptide chain is synthesized, it passes through...
27.5K
Termination of Translation01:44

Termination of Translation

6.6K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.0K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
9.0K